Published on 17 Apr 2023 on Simply Wall St. via Yahoo Finance
There's No Escaping Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Muted Revenues
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 11.5x and even P/S above 50x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.
View our latest analysis for Lyell Immunopharma
